8-K: Revelation Biosciences Reports Groundbreaking PRIME Study Results

Revelation Biosciences announced positive top-line results from its Phase 1b PRIME clinical study for Gemini in chronic kidney disease patients, demonstrating significant reduction in inflammatory activity and restored cellular response.

Summary

• Revelation Biosciences announced positive safety and activity data from its Phase 1b PRIME clinical study for Gemini in stage 3 and 4 chronic kidney disease (CKD) patients.
• The primary endpoint, evaluating the safety and tolerability of escalating doses of Gemini, was successfully met.
• Gemini significantly reduced inflammatory activity and restored normal cellular response to stimuli in peripheral blood mononuclear cells (PBMCs) isolated from patients.
• The observed effects were durable, measured at predose, 2, 24, and 168 hours post-dose, indicating Gemini's ability to rebalance the inflammatory process at the cellular level for up to 7 days.
• The PRIME study enrolled 40 patients, aged 32 to 78 years, across three US clinics specializing in CKD care.
• Patients were divided into five cohorts (8 patients per cohort, 6 treated/2 placebo) across four dose levels: subtherapeutic, low, target (cohorts 3 and 4), and high.
• In patients with high background PBMC activity (>40 pg/mL IL-1), Gemini significantly reduced inflammation relative to placebo (IL-1: p<0.01; TNF-: p=0.05; IL-6: p<0.01; IL-10: p<0.01; IL-1RA: p<0.001).
• Background inflammation in these patients was reduced to levels comparable to PBMCs isolated from healthy subjects.
• Gemini also significantly increased responsiveness to LPS stimulation (IL-1: p<0.0001; TNF-: p<0.002; IL-6: p<0.0002; IL-10: p=0.09; IL-1RA: p<0.01) and HMGB1 stimulation (IL-1: p<0.05; TNF-: p<0.01; IL-6: p<0.01; IL-10: p<0.05; IL-1RA: p<0.002) in high background patient PBMCs.
• Gemini administration was well-tolerated at the target dose, with all reported adverse events being mild (Grade I), including transient headache, chills, loose stool, and body aches.
• Three severe (Grade III) adverse events (chills, nausea, vomiting) were reported at the highest dose, but all resolved within 3 hours or less.
• No serious adverse events were reported, and no clinically significant trends were observed in safety blood/urinalysis parameters, vital signs, or ECG assessments.

Sentiment

Score: 9

Explanation: The filing reports 'groundbreaking' and 'positive' top-line results from a Phase 1b clinical study, meeting its primary safety endpoint and demonstrating significant, durable anti-inflammatory activity and restoration of cellular function in CKD patients. Management and investigators express strong optimism about Gemini's potential as a 'game-changer' for acute and chronic inflammation, indicating a highly favorable outcome.

Positives

• Met the primary endpoint of safety and tolerability for Gemini in CKD patients.
• Demonstrated significant reduction in inflammatory activity at the cellular level.
• Restored normal cellular response to stimuli, correcting immunoparalysis typical in chronic disease.
• Observed durable effects lasting up to 7 days after a single dose of Gemini.
• Gemini was well-tolerated at the target dose with only mild, transient adverse events.
• Results are consistent with previous healthy volunteer studies and preclinical findings, validating the drug's pharmacology.
• No serious adverse events were reported during the study.
• The data suggests Gemini could potentially revolutionize the treatment of acute and chronic inflammatory diseases.

Negatives

• Three severe (Grade III) adverse events (chills, nausea, vomiting) were reported at the highest dose, although they resolved quickly.
• The p-value for IL-10 responsiveness to LPS stimulation was 0.09, which is borderline for statistical significance (typically p<0.05 is desired).

Risks

• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially.
• Ability to meet financial and strategic goals may be impacted by competition.
• Challenges in growing and managing growth profitably and retaining key employees.
• Potential adverse effects from other economic, business, and/or competitive factors.
• Risks related to the successful development of product candidates.
• Uncertainty regarding the ability to successfully complete planned clinical studies.
• Risk that clinical studies may not fully enroll or enrollment may take longer than expected.
• Risks relating to the occurrence of adverse safety events and/or unexpected concerns arising from clinical study data.
• Changes in applicable laws or regulations could impact development.
• Uncertainty regarding the outcome of clinical data, including whether results are positive or replicable.
• The anticipated treatment of future clinical data by regulatory authorities (e.g., FDA, EMA) is not guaranteed to be sufficient for approval.
• Success of future development activities for product candidates is not assured.
• Ability to maintain the listing of securities on NASDAQ.
• The expected duration over which balances will fund operations is a risk factor.

Future Outlook

Revelation Biosciences looks forward to a scheduled End of Phase 1 meeting with the FDA later this year to discuss the advancement of the Gemini program. The company plans to publish these results and those from ongoing additional data analysis. Management believes Gemini has the potential to be a game-changer and could revolutionize the treatment of acute and chronic inflammatory diseases.

Management Comments

• "The activity observed with a single dose of Gemini in patients is shocking. This effect suggests a meaningful step forward in addressing the underlying immune dysregulation observed in patients with chronic kidney disease, and I am intrigued by the potential of Gemini to treat multiple types of acute and chronic inflammation." Principal Investigator Adam Horeish, MD, Balboa Research.
• "The results from this Phase 1b study represent a possible breakthrough in the treatment of inflammation. By addressing the inflammatory component of CKD, we may be able to improve patient outcomes and bring meaningful benefit to those living with this challenging condition. We look forward to working with the Revelation team to advance Gemini as a potential treatment for CKD." Principal Investigator Pablo Pergola, MD, PhD, Research Director at Clinical Advancement Center, PLLC.
• "The clear results from the PRIME study demonstrate the power of Gemini to elicit trained immunity. It is highly validating to see results consistent with the findings from our animal studies, as I would have expected. The strength of the effect of a single dose reinforces my confidence in the potential of Gemini as a promising treatment for burn patients." Julia K. Bohannon, Ph.D., Associate Professor, Vanderbilt University Medical Center.
• "The results of the PRIME study demonstrate the potential of Gemini to be a game-changer in the treatment of acute and chronic inflammation. We look forward to our scheduled End of Phase 1 meeting with the FDA later this year to discuss the advancement of this exciting program." James Rolke, Chief Executive Officer of Revelation.

Industry Context

Chronic kidney disease is a pervasive global health problem, often initiated and propagated by chronic inflammation stemming from conditions like diabetes and high blood pressure. Current treatments frequently lead to end-stage renal disease, necessitating dialysis or transplantation. Gemini's approach of rebalancing inflammation at the cellular level could represent a significant advancement in addressing the underlying causes of CKD and other inflammatory diseases, potentially offering a new therapeutic paradigm beyond symptomatic management and improving patient outcomes in a large, underserved market.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Potential for significant positive impact on stock value due to highly encouraging clinical trial results for a lead drug candidate in a major disease area, suggesting de-risking and future value creation.
• Patients (CKD, inflammatory diseases): Potential for a new, effective treatment option that addresses underlying inflammation and restores cellular function, offering improved outcomes and quality of life where current options are limited.
• Medical Community: Introduction of a potentially "game-changing" therapeutic approach for acute and chronic inflammation, which could lead to new treatment paradigms and further research opportunities.
• Employees: Positive clinical results can boost morale, attract talent, and provide job security through continued drug development and potential commercialization.

Next Steps

• Host a corporate update webcast/conference call on September 10, 2025, to review the top-line data and its potential impact.
• Conduct a scheduled End of Phase 1 meeting with the FDA later this year to discuss the advancement of the Gemini program.
• Seek to publish these results and those from ongoing additional data analysis.
• Continue development of Gemini for other indications, including prevention for post-surgical infection and acute kidney injury.

Key Dates

Recommendation

The positive top-line results from the PRIME Phase 1b study for Gemini in chronic kidney disease patients are highly encouraging, demonstrating both safety and significant, durable efficacy in rebalancing inflammation at the cellular level. This represents a potential breakthrough in treating a pervasive condition and other inflammatory diseases. The strong clinical data, coupled with enthusiastic statements from investigators and management, suggests a significant de-risking event for the company's lead asset and opens up substantial market opportunities, warranting a strong buy recommendation for investors.

Keywords

Revelation Biosciences, Gemini, Chronic Kidney Disease, CKD, Inflammation, Clinical Study, Phase 1b, PRIME, TLR4 agonist, Biotechnology, Life Sciences, Drug Development, Inflammatory Disease